Research use only — not for human or veterinary use
BPC-157 For Sale — Research Vials, Capsules and the TB-500 Stack
BPC-157 is a synthetic pentadecapeptide — fifteen amino acids, sequence GEPPPGKPADDAGLV — derived from a partial sequence of human gastric juice protein BPC. Unlike most peptides of comparable size it is notably stable in acidic conditions, which is the property that first drew attention to it and the reason oral-format research articles exist alongside the standard lyophilized vial. We supply BPC-157 as a 10 mg research vial, as a 1000 mcg capsule format, and as a co-formulated stack with TB-500 for soft-tissue signalling models. Supplied strictly for in vitro laboratory research — not for human or veterinary use.
Compare BPC-157 Research Formats
Three distinct research articles, each suited to a different class of experiment. Availability tracks live inventory; check the product page for the current status.
| Option | Format | Suited to | Product page |
|---|---|---|---|
| BPC-157 10 mg vial | Lyophilized powder, single research vial | Concentration series, in vitro repair and migration assays | View BPC-157 10 mg vial → |
| BPC-157 1000 mcg capsules (120 count) | Fixed-unit oral research capsule | Oral-format handling, dissolution and stability research | View BPC-157 1000 mcg capsules (120 count) → |
| BPC-157 + TB-500 stack | Co-formulated lyophilized blend | Combined pentadecapeptide and thymosin-fragment pathway models | View BPC-157 + TB-500 stack → |
What Is BPC-157?
BPC-157 is a partial sequence of Body Protection Compound, a protein identified in gastric juice. The fifteen-residue fragment retains the biological activity that first interested investigators while being short enough to synthesise reliably by standard solid-phase chemistry. Its composition is unusual — four prolines and a high proportion of small, flexible residues — which contributes to its resistance to enzymatic and acidic degradation.
That stability is the single most cited practical property. Most peptides of similar length degrade quickly in low-pH conditions; BPC-157 does not, and published work has repeatedly noted its persistence in gastric-mimicking buffer. For laboratory purposes this means assays can be run over longer windows and in harsher media than the peptide's size would suggest.
It is worth being precise about what BPC-157 is not: it is not an approved drug in any jurisdiction, it has not completed the clinical development pathway, and the great majority of published work is preclinical. We supply it as a research chemical and make no claims about human application.
Signalling Pathways Studied in Preclinical Work
The most frequently examined axis in BPC-157 research is angiogenic signalling, particularly involving vascular endothelial growth factor receptor 2 and the downstream nitric oxide system. In vitro endothelial models typically read out tube formation, migration, and receptor phosphorylation, and BPC-157 is used as the test article against vehicle and reference angiogenic controls.
A second line of investigation concerns the nitric oxide system directly. Studies have examined how BPC-157 interacts with nitric oxide synthase activity and with pharmacological NO donors and inhibitors, using those tools to establish whether an observed effect is NO-dependent. Including both an NOS inhibitor arm and a donor arm is close to standard practice in this literature.
Growth factor and gene-expression readouts form a third cluster: studies commonly profile expression of growth-factor genes in fibroblast and tendon-derived cell cultures after exposure, using quantitative PCR panels. Because these are expression-level readouts, careful housekeeping-gene selection and vehicle matching matter substantially to the interpretation.
Vials, Capsules and the TB-500 Stack
The 10 mg lyophilized vial is the general-purpose research format. It supports mass-based reconstitution to any working concentration, serial dilution, and the concentration-response designs that most cell-culture protocols require. If a study needs a curve rather than a single point, this is the format to buy.
The 1000 mcg capsule, supplied in a 120-count container, is a fixed-unit oral research article. It is used where the format itself is the object of study — dissolution profiling, oral-stability comparison, handling and unit-consistency work — and it removes reconstitution variance at the cost of concentration flexibility.
The BPC-157 + TB-500 stack is a co-formulated blend of the pentadecapeptide with the thymosin β4 fragment TB-500. The two compounds are studied in overlapping soft-tissue contexts but through different mechanisms: BPC-157 through angiogenic and NO-linked signalling, TB-500 through actin-sequestering and cell-migration pathways. The blend exists for designs that want both engaged from one prepared solution; where the arms must be titrated independently, buy the two separately.
Common Research Applications
In vitro applications concentrate on cell-culture models of tissue repair: fibroblast and tenocyte proliferation and migration assays, scratch-wound closure models, endothelial tube-formation assays, and epithelial barrier-integrity work using transepithelial resistance measurements. In each case BPC-157 is the test article and the study asks whether the readout shifts relative to vehicle.
Gut-barrier research is a distinct and active sub-field, reflecting the peptide's gastric origin. Those models measure junctional protein expression and monolayer permeability rather than repair per se, and they usually run alongside an inflammatory challenge such as a cytokine cocktail.
Comparative work against other repair-associated peptides — TB-500, KPV, GHK-Cu, ARA-290 — is common, since these compounds are frequently discussed together but act through unrelated mechanisms. A shared plate and vehicle control makes that comparison meaningful.
- Fibroblast and tenocyte migration and proliferation assays
- Endothelial tube-formation and angiogenesis models
- Gut-barrier permeability and junctional protein expression
- Comparative panels against TB-500, KPV and GHK-Cu
Storage, Reconstitution and Working Practice
Sealed lyophilized vials should be kept frozen and protected from light and moisture for long-term storage; short holds at 2–8 °C are acceptable. Because BPC-157 is hygroscopic in the lyophilized state, always let the vial equilibrate to room temperature before breaking the seal so that atmospheric moisture does not condense onto the cake.
Reconstitute with bacteriostatic water added slowly down the vial wall and swirl gently until the solution is clear. BPC-157 dissolves readily and should not require warming or extended agitation; if a cake resists dissolution, that usually indicates moisture ingress rather than a concentration problem.
Keep the reconstituted solution refrigerated, protected from light, and label the vial with the reconstitution date. Where a protocol has multiple sampling points, aliquot immediately and freeze the aliquots rather than withdrawing repeatedly from a single stock vial.
Material Specifications
- Compound
- BPC-157 (Body Protection Compound-157)
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Molecular formula
- C62H98N16O22
- Molar mass
- ≈ 1,419 g/mol
- Appearance
- White lyophilized powder (vials)
- Purity
- ≥ 99% by reverse-phase HPLC
- Storage
- Sealed vials frozen; reconstituted 2–8 °C
- Use
- In vitro laboratory research only
Purity, Testing & Certificates of Analysis
BPC-157 is released against reverse-phase HPLC purity criteria with mass-spectrometry identity confirmation. For a proline-rich sequence, deletion impurities are the realistic synthesis failure mode, so the release review looks specifically at the resolution of closely eluting related substances rather than only at the headline integrated purity.
The co-formulated BPC-157 + TB-500 blend is additionally assessed to confirm both components are present and chromatographically resolvable, because a blend whose ratio cannot be verified is not usable as a quantitative research article.
Every shipment references a dated, lot-specific Certificate of Analysis recording purity, identity, water content, appearance and assay date, and those certificates remain retrievable after purchase for attaching to study records.
Research FAQ
What is BPC-157 used for in research?
BPC-157 is used as a test article in in vitro tissue-repair models: fibroblast and tenocyte migration and proliferation assays, scratch-wound closure, endothelial tube formation, and gut-barrier permeability work. It is a research chemical only, not a medicine, and we provide no dosing or protocol guidance.
Which BPC-157 format should a laboratory choose?
Choose the 10 mg lyophilized vial for any study needing a chosen working concentration or a dilution series. Choose the 1000 mcg capsules when the fixed oral unit itself is the object of study, such as dissolution or handling research. Choose the TB-500 stack when both pathways should be engaged from one prepared solution.
What is the difference between BPC-157 and TB-500?
They are unrelated molecules studied in overlapping contexts. BPC-157 is a fifteen-residue gastric-derived peptide most associated with angiogenic and nitric-oxide-linked signalling; TB-500 is a fragment of thymosin β4 associated with actin sequestering and cell migration. The stack co-formulates both for combined-pathway designs.
Why is BPC-157 described as unusually stable?
Its proline-rich, small-residue composition resists enzymatic and acidic degradation, and published work has repeatedly noted its persistence in gastric-mimicking low-pH buffer. In practice that means assays can be run over longer windows and in harsher media than a fifteen-residue peptide would normally tolerate.
What purity is your BPC-157?
BPC-157 is released at ≥99% chromatographic purity by reverse-phase HPLC with mass-spectrometry identity confirmation, and each lot ships against a dated Certificate of Analysis recording purity, identity, water content, appearance and assay date.
How should BPC-157 be stored and reconstituted?
Keep sealed vials frozen and protected from light and moisture, letting them reach room temperature before opening. Reconstitute with bacteriostatic water added slowly down the vial wall, swirl gently until clear, then store at 2–8 °C, label the reconstitution date, and aliquot if multiple sampling points are planned.
Is BPC-157 approved for human use?
No. BPC-157 is not an approved drug in any jurisdiction and the great majority of published work is preclinical. It is supplied here exclusively as a research chemical for qualified in vitro laboratory use, and it is not for human or veterinary consumption.
Where do BPC-157 orders ship from?
Orders are fulfilled from our Jacksonville, Florida facility and dispatched the same business day when placed before the daily cut-off, with domestic transit typically one to two business days and packaging matched to the expected transit profile.
Research Resources
All products listed are supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary use. We do not provide dosing guidance or therapeutic recommendations, and nothing on this page describes a diagnosis, treatment, cure, or prevention of any condition.